Correlation Between Raphael Pharmaceutical and Procaps Group

Can any of the company-specific risk be diversified away by investing in both Raphael Pharmaceutical and Procaps Group at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Raphael Pharmaceutical and Procaps Group into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Raphael Pharmaceutical and Procaps Group SA, you can compare the effects of market volatilities on Raphael Pharmaceutical and Procaps Group and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Raphael Pharmaceutical with a short position of Procaps Group. Check out your portfolio center. Please also check ongoing floating volatility patterns of Raphael Pharmaceutical and Procaps Group.

Diversification Opportunities for Raphael Pharmaceutical and Procaps Group

-0.78

Correlation Coefficient

Raphael Pharmaceutical  Procaps Group

Pay attention - limited upside

The 3 months correlation between Raphael and Procaps is -0.78. Overlapping area represents the amount of risk that can be diversified away by holding Raphael Pharmaceutical and Procaps Group SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Procaps Group SA and Raphael Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Raphael Pharmaceutical are associated (or correlated) with Procaps Group. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Procaps Group SA has no effect on the direction of Raphael Pharmaceutical i.e., Raphael Pharmaceutical and Procaps Group go up and down completely randomly.

Pair Corralation between Raphael Pharmaceutical and Procaps Group

Given the investment horizon of 90 days Raphael Pharmaceutical is expected to generate 0.88 times more return on investment than Procaps Group. However, Raphael Pharmaceutical is 1.14 times less risky than Procaps Group. It trades about 0.2 of its potential returns per unit of risk. Procaps Group SA is currently generating about 0.01 per unit of risk. If you would invest  26.00  in Raphael Pharmaceutical on December 29, 2024 and sell it today you would earn a total of  74.00  from holding Raphael Pharmaceutical or generate 284.62% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	95.31%
Values	Daily Returns

Raphael Pharmaceutical  vs.  Procaps Group SA

Raphael Pharmaceutical

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Raphael Pharmaceutical are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite fairly fragile basic indicators, Raphael Pharmaceutical demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Procaps Group SA

Risk-Adjusted Performance

Very Weak

Over the last 90 days Procaps Group SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather weak basic indicators, Procaps Group may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Raphael Pharmaceutical and Procaps Group

The main advantage of trading using opposite Raphael Pharmaceutical and Procaps Group positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Raphael Pharmaceutical position performs unexpectedly, Procaps Group can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Procaps Group will offset losses from the drop in Procaps Group's long position.

The idea behind Raphael Pharmaceutical and Procaps Group SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.